Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kazuhiro Kitamura

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Oncology Letters|August 8, 2012
HSP27 modulates epithelial to mesenchymal transition of lung cancer cells in a Smad-independent mannerHideaki Mizutani, Tetsuya Okano, Yuji Minegishi, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2012
Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusionKazuhiro Kitamura, Kaoru Kubota, Masahiro Ando, et al.
BMC Cancer|April 18, 2015
MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutationRintaro Noro, Masahiro Seike, Fenfei Zou, et al.
BMC Cancer|May 30, 2013
Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutationAkihiko Miyanaga, Kumi Shimizu, Rintaro Noro, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Oncology Letters|August 8, 2012
HSP27 modulates epithelial to mesenchymal transition of lung cancer cells in a Smad-independent mannerHideaki Mizutani, Tetsuya Okano, Yuji Minegishi, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2012
Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusionKazuhiro Kitamura, Kaoru Kubota, Masahiro Ando, et al.
BMC Cancer|April 18, 2015
MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutationRintaro Noro, Masahiro Seike, Fenfei Zou, et al.
BMC Cancer|May 30, 2013
Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutationAkihiko Miyanaga, Kumi Shimizu, Rintaro Noro, et al.
Pageof 2